Guidelines for Dengue and Dengue Haemorrhagic Fever

Objectives

The guidance establishes a combined clinical and public-health framework for dengue and dengue haemorrhagic fever (DHF), addressing disease occurrence, transmission, clinical characteristics, treatment, immunisation, and prevention and control.[1]Its overarching purpose is to limit severe illness and deaths from DHF while reducing dengue transmission in settings where the disease and its mosquito vectors are expanding geographically.[1][2]The framework recognises that four related dengue viruses cause disease, that infection produces lifelong immunity only to the infecting serotype, and that subsequent infection with a different serotype may increase the risk of severe dengue and DHF.[1]

• Reduce DHF mortality through prompt, careful clinical management and intensive supportive treatment, centred on maintaining circulating fluid volume.[3]
• Prevent dengue transmission by controlling vector mosquitoes, especially the predominantly urban Aedes aegypti, and by reducing household and environmental breeding opportunities.[2][3]
• Strengthen environmental management, chemical vector control, community action, and surveillance as complementary elements of dengue prevention and control.[3]
• Recognise the limitations of immunisation at the time of the guidance: vaccine development is complicated by the need to protect against all four viruses and by concern that partial protection may heighten the risk of severe disease.[3]
• Prepare for the potential public-health use of vaccines that provide protection against all four dengue viruses, should such products become available.[3]

Implementation

Implementation combines experienced clinical care for severe cases with integrated vector control focused on domestic and urban breeding sites.[2][3]Infected humans are identified as the principal amplifying host, while mosquito populations are sustained by water-storage practices, waste, discarded containers, used tyres, and similar habitats around homes and communities.[2][3]The guidance was developed by the Epidemic Investigation Cell of the Public Health Laboratories Division at the National Institute of Health, Islamabad, in collaboration with the World Health Organization.[1]

• Provide DHF patients with care from experienced physicians and nurses, using intensive supportive therapy and close attention to circulating fluid volume; this approach can reduce mortality to less than 1%.[2][3]
• Improve solid-waste disposal and household water-storage practices, including covering water containers so that egg-laying mosquitoes cannot access them.[3]
• Apply insecticides to appropriate larval habitats, particularly household water-storage vessels, and repeat application periodically where needed.[3]
• Consider biological methods, including mosquito-eating fish and copepods, where locally appropriate.[3]
• Use emergency space spraying during outbreaks when required, while accounting for its short-lived effect, inconsistent penetration of indoor mosquito habitats, high cost, and considerable operational requirements.[3]
• Engage communities in identifying and eliminating domestic breeding sites and in sustaining preventive water-storage and waste-management practices.[3]
• Monitor mosquito susceptibility to commonly used insecticides regularly to inform the selection of chemical-control measures.[3]
• Conduct active monitoring and surveillance of natural mosquito populations alongside vector-control activities to assess programme impact.[3]
• Note that formal reporting arrangements, performance indicators, evaluation schedules, accountability mechanisms, budgets, financing sources, and quantified resource needs are not specified.[1][2][3]

Monitoring & Evaluation

Dengue prevention and control require epidemiological awareness, vector surveillance, clinical monitoring and assessment of control measures. The available material describes disease occurrence, attack rates, hospitalisation and case-fatality patterns, but does not establish a formal national monitoring and evaluation framework, standard indicator set, reporting chain, review timetable or accountability mechanism.[1][2]

• Monitor the geographic expansion of dengue viruses and mosquito vectors as an epidemiological risk requiring continuing public-health attention.[2]
• Monitor mosquito susceptibility to commonly used insecticides regularly so that chemical-control measures can be selected appropriately.[3]
• Conduct active monitoring and surveillance of natural mosquito populations alongside vector-control activities to assess their impact.[3]
• Track clinical outcomes associated with dengue haemorrhagic fever management, as experienced physician and nursing care with intensive supportive therapy can reduce mortality to below 1%.[3]
• Use available epidemiological information on prevalence, reported cases, attack rates, hospitalisation and case fatality to inform the understanding of dengue burden; the material does not specify how these data should be collected, validated, reported or used for performance assessment.[1][2]
• Recognise that no explicit targets are provided for vector density, insecticide susceptibility, case detection, treatment coverage, mortality reduction, community participation or environmental-management performance.[3]
• Clarify institutional responsibility for surveillance, reporting, programme review and corrective action, as the source identifies the Epidemic Investigation Cell of the Public Health Laboratories Division at the National Institute of Health, Islamabad, and the World Health Organization as contributors to development of the guidance, but does not assign implementation accountability.[1]

Costing & Financing

Costing and financing arrangements are not specified. No programme budget, resource-mobilisation plan, funding source, allocation, funding gap, unit cost, economic appraisal or quantified assumption is provided for clinical care, vector control, surveillance, environmental management or community action.[1][2][3]

• Recognise that emergency space spraying during outbreaks is described as high-cost and operationally demanding, with only transient effects and variable ability to reach indoor mosquito habitats.[3]
• Consider resource requirements for repeated insecticide application to suitable larval habitats, particularly domestic water-storage vessels, although no cost or financing details are provided.[3]
• Consider operational inputs for solid-waste disposal, water-storage improvements, container covering, community-based activities, mosquito-eating fish, copepods and surveillance; the source provides no associated financial estimates or funding arrangements.[3]
• Recognise that intensive supportive therapy and experienced clinical staffing are central to dengue haemorrhagic fever management, but no treatment costs, facility budget requirements or workforce financing arrangements are specified.[3]
• Avoid inferring comparative cost-effectiveness between environmental, biological, chemical and emergency spraying interventions because the available material supplies no numerical expenditure or economic-effectiveness evidence.[3]